Compare Vanguard Emerging Markets Stock Index Fund ETF (VWO) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Emerging Markets Stock Index Fund ETF vs Zimmer Biomet Holdings Inc — how do they compare? Vanguard Emerging Markets Stock Index Fund ETF trades at $59.76 (market cap $168.50B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Vanguard Emerging Markets Stock Index Fund ETF is far larger — about 9.9× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Vanguard Emerging Markets Stock Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Emerging Markets Stock Index Fund ETF for 135 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| VWO | ZBH | |
|---|---|---|
Market Cap | $168.50B | $16.95B |
Volume | 9,650,999 | 2,505,240 |
52-Week High | $61.44 | $103.98 |
52-Week Low | $52.42 | $79.58 |
Typical Hold Time | 135 Days | 89 Days |
Sector | — | Health |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VWO trades at $59.10, down 1.25% with a bearish technical signal from moving averages. The ETF faces mixed sentiment as AI-driven Taiwan exposure provides strength while China's economic slowdown weighs on performance. Recent institutional buying by Allianz and Alamar Capital contrasts with technical weakness.
The emerging markets ETF offers diversification but faces headwinds from China's property and consumer weakness. Technical indicators suggest caution near-term, though institutional accumulation and AI infrastructure demand provide potential catalysts for patient investors.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
